ArticleHeliyon2024

Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study.

Guosheng Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.